AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Summit Therapeutics Inc. Director's Dealing 2022

Apr 26, 2022

30436_dirs_2022-04-26_44ec4311-59e2-4cf4-ab2f-e1d14b24e58d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2022-04-25

Reporting Person: Gayko Urte (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-25	Stock Option (right to buy)	$1.93	A	400000	Acquired	2032-04-25	Common Stock (400000.0)	Direct

Footnotes

F1: The option was granted on April 25, 2022. The shares underlying the option are scheduled to vest in four equal annual installments over four years.

F2: Not applicable.